Replies to post #179005 on Biotech Values

[DewDiligence]

[Dew]: A competitive pan-genotypic all-oral regimen for HCV does not have to contain a nuke.

[oc631]: …I personally disagree...

In that case, you’re implicitly predicting that the nuke-free regimen of ABT-593 + ABT-530 and the nuke-free regimen of Alisporvir + EDP-239 will fail. I’ll make a note of that!